Incyte said its total GAAP revenues for 2023 were $3,695,649 thousand and its total GAAP revenues for Q4 were $1,013,341 thousand, while its net product and royalty revenues for the year were $3.7 billion (+14%).

1. 01

   Incyte said its total GAAP revenues for 2023 were $3,695,649 thousand and its total GAAP revenues for Q4 were $1,013,341 thousand, while its net product and royalty revenues for the year were $3.7 billion (+14%).

2. 02

   The company said its Jakafi net revenues for 2023 were $2.59 billion (+8%), its Opzelura net revenues were $338 million, and its Opzelura net revenues for Q4 were $109 million (+78%). It also said Jakafi revenues for Q4 were negatively affected by an increase in the number of Medicare Part D patients receiving free product and positively affected by an increase in channel inventory.

3. 03

   Incyte reported GAAP net income of $597,599 thousand for 2023 (2022 $340,660 thousand) and GAAP operating income of $620,525 thousand (2022 $579,440 thousand). GAAP net income for Q4 was $201,079 thousand.

4. 04

   The company set its Jakafi net revenues guidance for 2024 at $2,690 to $2,750 million. It said it paid $25 million to MorphoSys AG under an asset purchase agreement that gave it exclusive global rights to tafasitamab.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the opening part of the filing body and confirmed exhibits, within a length limit. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.